Larimar Therapeutics, Inc. (LRMR) earnings date, results and what the price requires
Nasdaq · SEC CIK 0001374690 · SEC filings checked Oct 17, 2026
Next report
Nov 11, 2026
Estimated from reporting history (99-day cycle, SEC 8-K item 2.02 results filings). Not confirmed.
Last close
$1.99
Polygon.io daily close, Oct 16, 2026. End of day, not live.
Trailing diluted EPS
$-1.95
Sum of quarters ending Sep 30, 2025, Jun 30, 2025, Mar 31, 2025, Dec 31, 2024
Previous results (SEC filings)
| Quarter ended | Reported | Revenue | Net income | Diluted EPS | Source |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 4, 2026 | Announced; figures arrive with the 10-Q | $-32.8M | — | Filing |
| Mar 31, 2026 | May 14, 2026 | Announced; figures arrive with the 10-Q | $-29.6M | — | Filing |
| Dec 31, 2025 | Jan 12, 2026 | Announced; figures arrive with the 10-Q | $-62.5M | — | Filing |
| Sep 30, 2025 | Nov 5, 2025 | — | $-47.7M | $-0.61 | Filing |
| Jun 30, 2025 | Jul 29, 2025 | — | $-26.2M | $-0.41 | Filing |
| Mar 31, 2025 | Apr 30, 2025 | — | $-29.3M | $-0.46 | Filing |
| Dec 31, 2024 | Mar 24, 2025 | — | $-28.8M | $-0.47 | Filing |
| Sep 30, 2024 | Oct 30, 2024 | — | $-15.5M | $-0.24 | Filing |
What would Larimar Therapeutics, Inc. have to report for its valuation to change?
Trailing earnings are negative, so a price-to-earnings reverse model does not apply. The model is not shown rather than filled with assumptions.
Figures come from SEC EDGAR XBRL filings. Dates marked "estimated" are calculated from the company's past results filings and are not confirmed. Not investment advice.